Stockscreener 앱 받기
6.32
3.61%
0.22
시장 영업 전:
6.33
0.010
+0.16%
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Will Myriad Genetics Inc. rebound enough to break evenShort-Term Stock Trend Forecast Guide - Newser
What’s next for Myriad Genetics Inc. stock priceHigh Return Trade Roadmap with Setup Filters - Newser
Is Myriad Genetics Inc. meeting your algorithmic filter criteriaScalable Strategy with Chart Confirmation - Newser
Historical volatility pattern of Myriad Genetics Inc. visualizedBuy Candidate Summary Based on Fundamentals - Newser
Myriad Genetics Raises FY25 Revenue and EBITDA Forecasts, Exceeding Market Consensus - AInvest
Myriad Genetics shares fall 1.48% premarket after UBS lowered its price target to $6. - AInvest
Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus - MSN
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - uk.finance.yahoo.com
Myriad Genetics 2025 Q2 Earnings Misses Targets as Net Loss Widens 800.5% - AInvest
CareDx Names Nathan Smith as New CFO - AInvest
Myriad Genetics Reports 1% YoY Revenue Growth in Q2 2025 - AInvest
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth - Seeking Alpha
Why Is Myriad Genetics (MYGN) Stock Soaring Today - Yahoo Finance
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet and Other Big Stocks Record Gains on Wednesday - AInvest
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
Myriad Genetics Stock Soars 30.49% on Strong Q2 Earnings - AInvest
Myriad Genetics shares surge 30.49% in premarket after reporting strong Q2 earnings and raising 2025 revenue guidance. - AInvest
Myriad Genetics 2025 Q2 Earnings Deepening Losses Amid Raised Revenue Guidance - AInvest
MYRIAD GENETICS INC SEC 10-Q Report - TradingView
Myriad Genetics (MYGN) Reports Revenue Growth, Strategic Shifts - GuruFocus
Myriad Genetics: Leveraging Strategic Overhaul and Market Tailwinds for a Comeback in Precision Medicine - AInvest
Myriad Genetics Q2 2025: Unraveling Contradictions in Strategic Focus, GeneSight Performance, and Oncology Growth - AInvest
Myriad Genetics Aims for High Single-Digit to Low Double-Digit Growth through Cancer Care Continuum Focus. - AInvest
Myriad Genetics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics Updates 2025 Revenue Guidance Amid Growth - TipRanks
Myriad Genetics (MYGN) Q2 Revenue Up 6% - AOL.com
Myriad Genetics Surges After Hours on Strong Q2 Earnings and Raised Revenue Guidance - AInvest
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance - inkl
Hold Rating Maintained for Myriad Genetics Amid Mixed Performance and Strategic Challenges - TipRanks
Myriad Genetics Edges Past Estimates And Lifts Revenue Outlook - Finimize
Earnings call transcript: Myriad Genetics beats Q2 2025 expectations with revenue growth - Investing.com Canada
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics - Nasdaq
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates - sg.finance.yahoo.com
Myriad Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Myriad: Q2 Earnings Snapshot - San Francisco Chronicle
Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c) - TipRanks
Myriad Genetics Q2 2025 slides: revenue growth accelerates, guidance raised - Investing.com
Myriad Genetics Reports Q2 Revenue Ahead of Estimates, Stock Jumps 30.6% - AInvest
Myriad Genetics earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6% - Yahoo Finance
Myriad Genetics Q2 revenue up 1% YoY, raises FY23 guidance. - AInvest
Myriad Genetics Reports Second Quarter 2025 Financial - GlobeNewswire
[8-K] Myriad Genetics Inc Reports Material Event | MYGN SEC FilingForm 8-K - Stock Titan
Prenatal care is evolving with Myriad - WFLA
Price Channel Expanding on Myriad Genetics Inc.’s ChartLow Risk Equity Screener With Results Shared - metal.it
Myriad Genetics Inc. Recovery Likely Here’s What Data ShowsLow Risk Swing Trade Opportunities Identified - metal.it
Myriad Genetics Q2 2025 Earnings: A Pivotal Moment for a Cash-Burning Biotech - AInvest
Earnings To Watch: Myriad Genetics (MYGN) Reports Q2 Results Tomorrow - Yahoo Finance
How strong is Myriad Genetics Inc. company’s balance sheetSuperior profit margins - Jammu Links News
How does Myriad Genetics Inc. generate profit in a changing economyExponential wealth increase - Jammu Links News
What is Myriad Genetics Inc. company’s growth strategyNavigate market shifts with confidence - Jammu Links News
What is the risk reward ratio of investing in Myriad Genetics Inc. stockExplosive capital gains - Jammu Links News
Is Myriad Genetics Inc. a growth stock or a value stockDiscover high-impact stocks for your portfolio - Jammu Links News
Myriad Genetics Inc. Stock Analysis and ForecastAchieve consistent profits with proven strategies - Jammu Links News
How does Myriad Genetics Inc. compare to its industry peersDiscover stocks with explosive upside potential - Jammu Links News
Published on: 2025-08-03 11:23:27 - Jammu Links News
What are the latest earnings results for Myriad Genetics Inc.Capitalize on market momentum for profits - Jammu Links News
How volatile is Myriad Genetics Inc. stock compared to the marketUnstoppable trading performance - Jammu Links News
How many analysts rate Myriad Genetics Inc. as a “Buy”Market-crushing stock picks - Jammu Links News
Does Myriad Genetics Inc. stock perform well during market downturnsSky-high return potential - Jammu Links News
Myriad Genetics, Inc. (NASDAQ:MYGN) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough - 富途牛牛
1.15%
자본화:
|
볼륨(24시간):